

**FORWARDHEALTH  
PRIOR AUTHORIZATION DRUG ATTACHMENT  
FOR HYPOGLYCEMICS, GLUCAGON-LIKE PEPTIDE (GLP-1) AGENTS**

**INSTRUCTIONS:** Type or print clearly. Before completing this form, read the Prior Authorization Drug Attachment for Hypoglycemics, Glucagon-Like Peptide (GLP-1) Agents Instructions, F-00238A. Prescribers may refer to the Forms page of the ForwardHealth Portal at <https://www.forwardhealth.wi.gov/WIPortal/Subsystem/Publications/ForwardHealthCommunications.aspx?panel=Forms> for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization Drug Attachment for Hypoglycemics, Glucagon-Like Peptide (GLP-1) Agents form signed and dated by the prescriber before submitting a prior authorization (PA) request on the Portal, by fax, or by mail. Prescribers and pharmacy providers may call Provider Services at 800-947-9627 with questions.

---

**SECTION I – MEMBER INFORMATION**

---

1. Name – Member (Last, First, Middle Initial)

2. Member ID Number

3. Date of Birth – Member

---

**SECTION II – PRESCRIPTION INFORMATION**

---

4. Drug Name

5. Drug Strength

6. Date Prescription Written

7. Refills

8. Directions for Use

9. Name – Prescriber

10. Address – Prescriber (Street, City, State, Zip+4 Code)

11. Phone Number – Prescriber

12. National Provider Identifier – Prescriber

---

**SECTION III – CLINICAL INFORMATION**

---

13. Diagnosis Code and Description

14. Is the non-preferred drug being prescribed in a manner consistent with the Food and Drug Administration-approved product labeling?

☐ Yes

☐ No

15. Does the member have type 2 diabetes mellitus?

☐ Yes

☐ No



16. Indicate the member's most recent hemoglobin A1c (HbA1c).

\_\_\_\_\_. \_\_\_\_ %

17. Date Member's HbA1c Measured (Within the Past Six Months)

\_\_\_\_ / \_\_\_\_ / \_\_\_\_  
Month Date Year

18. List the member's current hypoglycemics, GLP-1 therapy, or check None if appropriate.

☐ None

Drug Name \_\_\_\_\_ Dose \_\_\_\_\_ Start Date \_\_\_\_\_

19. List the member's previous hypoglycemics, GLP-1 therapy and the reason(s) for discontinuation, or check None if appropriate.

☐ None

Drug Name \_\_\_\_\_ Dose \_\_\_\_\_ Dates Taken \_\_\_\_\_

Reason for Discontinuation \_\_\_\_\_

Drug Name \_\_\_\_\_ Dose \_\_\_\_\_ Dates Taken \_\_\_\_\_

Reason for Discontinuation \_\_\_\_\_

Drug Name \_\_\_\_\_ Dose \_\_\_\_\_ Dates Taken \_\_\_\_\_

Reason for Discontinuation \_\_\_\_\_

20. PA requests must include detailed documentation regarding why the member is unable to take or has previously discontinued **at least two** of the preferred hypoglycemics, GLP-1 treatments.

1. Byetta Documentation

2. Trulicity Documentation

3. Victoza Documentation

**SECTION IV – AUTHORIZED SIGNATURE**

21. <b>SIGNATURE</b> – Prescriber	22. Date Signed
-----------------------------------	-----------------

**SECTION V – ADDITIONAL INFORMATION**

23. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the drug requested may be included here.